Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ende...
In vivo study of M2 metabolite shows no signs of genotoxicity Marinus’ CDKL5 deficiency disorder marketing authorization application to convert to standard review timeline Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that company management will present virtually during the H.C. Wainwright Bioconnect Conference as well as t...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of M...
Data from an open-label extension of a phase 3 trial of Marinus Pharmaceuticals (MRNS -7.8%) ganaxolone for CDKL5 deficiency disorder ("CDD") showed the treatment led to a reduction in motor seizures at up to 12 months. The median major motor seizure frequency reduction from baseline was 30.1...
Webcast to be held Monday, December 6 at 1:00 p.m. ET (12:00 p.m. CT) Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced new clinical trial and re...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that nine abstracts highlighting clinical trial and research data have been accepted for poster presentatio...
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2021 Earnings Conference Call November 09, 2021, 08:30 AM ET Company Participants Sasha Damouni - VP, IR and Corporate Communications Scott Braunstein - CEO Joe Hulihan - Chief Medical Officer Steve Pfanstiel - CFO Conference Call Participants Joon Lee ...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Marinus Pharmaceuticals (NASDAQ:MRNS): GAAP EPS of -$0.53 beats by $0.12. Revenue of $10.11M beats by $4.95M. Press Release For further details see: Marinus Pharmaceuticals EPS beats by $0.12, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...